Laurens F. Reeskamp, MD, PhD; Tycho R. Tromp, MD, PhD; Aniruddh P. Patel, MD; et al.
free access
JAMA Cardiol. 2023;8(12):1111-1118. doi:10.1001/jamacardio.2023.3548
This cross-sectional study measures the association of lipoprotein(a) concentrations in pairs of first- and second-degree relatives of participants in the UK Biobank with high lipoprotein(a) levels.
Sofia Gonçalves Viamonte, MD; Ana Vieira Joaquim, MD; Alberto Jorge Alves, PhD; et al.
free access
JAMA Cardiol. 2023;8(12):1119-1128. doi:10.1001/jamacardio.2023.3558
This randomized clinical trial compares fitness improvements and control of cardiovascular risk factors among cancer survivors with cardiovascular disease and/or exposure to cardiotoxic cancer treatment who underwent center-based cardiac rehabilitation or usual care with community-based exercise training.
AI in Cardiology
Neal Yuan, MD; Grant Duffy, BS; Sanket S. Dhruva, MD, MHS; et al.
free access
JAMA Cardiol. 2023;8(12):1131-1139. doi:10.1001/jamacardio.2023.3701
This prognostic study investigates whether deep learning models applied to electrocardiograms (ECGs) of sinus rhythm in a population of US Veterans Affairs (VA) patients can predict the presence of concurrent atrial fibrillation (AF).
Mohit K. Turagam, MD; Petr Neuzil, MD, PhD; Boris Schmidt, MD; et al.
free access
JAMA Cardiol. 2023;8(12):1142-1151. doi:10.1001/jamacardio.2023.3752
This cohort study investigates if patient sex is associated with clinical outcomes of pulsed field ablation for the treatment of individuals with atrial fibrillation.
-
Invited Commentary
Pulsed Field Closes Gender Gap in Atrial Fibrillation Ablation鈥擡lectrifying Insights
Peter M. Kistler, MBBS, PhD; Louise Segan, MBBS, MPH
JAMA Cardiol
Divaka Perera, MA, MD; Matthew Ryan, PhD; Holly P. Morgan, MBBCh; et al.
open access
has audio
JAMA Cardiol. 2023;8(12):1154-1161. doi:10.1001/jamacardio.2023.3803
This secondary analysis of a randomized clinical trial assesses whether myocardial viability testing identifies patients with ischemic left ventricular dysfunction who benefit from percutaneous coronary intervention.
-
Podcast:
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction
-
Invited Commentary
Assessment of Myocardial Viability in Ischemic Cardiomyopathy鈥擲carred by the Data but Still Alive
Julio A. Panza, MD
JAMA Cardiol
-
Podcast:
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction
-
Editor's Note
Realigning Priorities in the Evaluation and Management of Patients With Heart Failure
James E. Udelson, MD; Gregg C. Fonarow, MD; Robert O. Bonow, MD, MS
JAMA Cardiol
Sean D. Pokorney, MD; Lindsay Zepel, MS; Melissa A. Greiner, MS; et al.
open access
JAMA Cardiol. 2023;8(12):1165-1173. doi:10.1001/jamacardio.2023.3379
This cohort study uses Medicare data to assess the number of patients with cardiac implantable electronic device infection who underwent device extraction from 2006 to 2019 and all-cause mortality associated with lead extraction.